Home » Risedronate » Search engine for other government resources

Risedronate MedlinePlus Drug Information Risedronate tablets and delayed-release (long-acting tablets) are used to prevent and treat osteoporosis (a condition in which the bones become thin ... medlineplus.gov/druginfo/meds/a601247.html Risedronate a new oral bisphosphonate Risedronate, the newest oral bisphosphonate, is approved by the US Food and Drug Administration for the prevention and treatment of postmenopausal ... pubmed.ncbi.nlm.nih.gov/11589256/ Risedronate sodium C7H10NNaO7P2 - PubChem Create. 2005-09-13. Risedronate Sodium is the sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to ... pubchem.ncbi.nlm.nih.gov/compound/Risedronate-sodium Efficacy and safety of risedronate 150-mg once a month in ... Introduction: Risedronate is effective in the treatment of postmenopausal osteoporosis in oral daily, weekly, or on two consecutive days per month ... pubmed.ncbi.nlm.nih.gov/22752050/ Efficacy of risedronate on clinical vertebral fractures ... Risedronate has been shown to reduce the incidence of radiographically-defined vertebral fractures by approximately two-thirds within 1 year. Research ... pubmed.ncbi.nlm.nih.gov/15119979/ A comparison of the effect of alendronate and risedronate ... Objectives: To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW with respect to change in bone mineral density (BMD), biochemical ... pubmed.ncbi.nlm.nih.gov/18324951/ Risedronate sodium monohydrate C7H12NNaO8P2 - PubChem Risedronate sodium monohydrate. Risedronate sodium hydrate. UNII-F67L43UT5C. F67L43UT5C. 353228-19-0 pubchem.ncbi.nlm.nih.gov/compound/Risedronate-sodium-monohydrate Risedronic acid C7H11NO7P2 - PubChem Risedronate binds to bone hydroxyapatite and, at the cellular level, inhibits osteoclasts. Although the osteoclasts adhere normally to the bone ... pubchem.ncbi.nlm.nih.gov/compound/Risedronic-acid Effects of Risedronate on Osteoarthritis of the Knee - PubMed The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature ... pubmed.ncbi.nlm.nih.gov/20191005/ Comparison of the effects of three oral bisphosphonate ... Greater effects were observed for ibandronate (and alendronate) than risedronate at the spine but not the hip. Introduction: Generally, comparative ... pubmed.ncbi.nlm.nih.gov/25074351/ Cost-effectiveness of gastro-resistant risedronate tablets ... The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with ... pubmed.ncbi.nlm.nih.gov/30701342/ WITHDRAWN Risedronate for the prevention and treatment of ... Risedronate, a third generation bisphosphonate, has been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density in ... pubmed.ncbi.nlm.nih.gov/17636764/ PDF HIGHLIGHTS OF PRESCRIBING INFORMATION ... FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE 1.1 Postmenopausal Osteoporosis . ACTONEL is indicated for the treatment and prevention of ... www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf PDF Actonel risedronate sodium Tablet Film Coated DESCRIPTION name of risedronate sodium is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt. The chemical structure of risedronate sodium ... www.accessdata.fda.gov/drugsatfda_docs/label/2007/020835s028lbl.pdf PDF OFFICE OF CLINICAL PHARMACOLOGY REVIEW Risedronate sodium is a pyridinyl bisphosphonate drug with the empirical formula for the hemipentahydrate as C7H10NO7P2Na 2.5 H2O [MW 350.13]. The ... www.accessdata.fda.gov/drugsatfda_docs/pediatric/020835s035_Risedronate_Clinpharm_BPCA.pdf DailyMed - RISEDRONATE SODIUM tablet film coated Risedronate is not indicated for use in pediatric patients. The safety and effectiveness of risedronate was assessed in a one-year, randomized ... dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a42a35e6-3e08-4b4f-ae56-47d4aec2322a History of risedronate - PubMed Risedronate was shown to significantly reduce serum alkaline phosphatase and clinical features in patients with Paget's disease and was approved for ... pubmed.ncbi.nlm.nih.gov/32387834/ DrugsFDA FDA-Approved Drugs Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS; ACTONEL: RISEDRONATE SODIUM: 30MG: TABLET;ORAL: Prescription ... www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020835 DailyMed - RISEDRONATE SODIUM tablet delayed release Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each risedronate sodium ... dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95fce48f-5ebc-4d49-a97c-1e4f2a71d507 PDF ACTONEL with CALCIUM DESCRIPTION ACTONEL with CALCIUM is ... The chemical name of risedronate sodium is [1-hydroxy-2-(3 pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt. The chemical structure of rised ... www.accessdata.fda.gov/drugsatfda_docs/label/2015/021823s011lbl.pdf